Literature DB >> 6185891

Megestrol acetate for the palliation of advanced ovarian carcinoma.

H E Geisler.   

Abstract

High doses of the oral progestin megestrol acetate were used to treat patients with ovarian cancer who had suffered relapses following conventional therapy. In all but 2 of these patients, second-line drugs or other additional therapeutic measures had been tried before resorting to the high-dose oral progestin. The response of 24 patients is the subject of this report. Megestrol acetate proved to be useful for those who were able to take oral medication and who failed to respond to other forms of therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6185891

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  2 in total

Review 1.  Developing new drugs for ovarian cancer: a challenging task in a changing reality.

Authors:  R M Canetta; S K Carter
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

2.  The occurrence of endometrial adenocarcinoma in a patient with basal cell nevus syndrome.

Authors:  M A Khalifa; G Patterson-Cobbs; C H Hansen; J F Hines; J C Johnson
Journal:  J Natl Med Assoc       Date:  1997-08       Impact factor: 1.798

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.